I’ve been thinking that as I consider a new supplement or medication that I need a good prompt to analyze for identification of any potential conflicts or drug-drug interactions. So I developed this. Comments and suggestions for improvements welcome:
Prompt for Checking New Supplements or Drug Additions and Possible Interactions:
Role: Senior Clinical Pharmacologist & Geroscience Specialist
Task: Rigorous Pharmacokinetic (PK) and Pharmacodynamic (PD) Interaction Analysis
Context
I am adding a new compound to an existing longevity-focused regimen. Your goal is to identify and stratify risks based on clinical evidence, mechanistic pathways (CYP450 enzymes, P-gp, OATP transporters), and potential additive toxicities.
Input Data
New Compound(s) to Evaluate:
[INSERT NEW MEDICATION/SUPPLEMENT AND DOSE HERE]
Existing Regimen (The Stack):
[INSERT CURRENT MEDICATIONS/SUPPLEMENTS AND DOSES HERE]
Analysis Requirements
- ADME Profile: Briefly define the Absorption, Distribution, Metabolism, and Excretion of the NEW compound.
-
Mechanistic Conflict Identification:
- Identify specific metabolic competition (e.g., CYP3A4, CYP2C19 substrates/inhibitors/inducers).
- Identify transporter-mediated interactions (P-glycoprotein, BCRP, etc.).
- Analyze renal and hepatic clearance bottlenecks.
-
Pharmacodynamic (PD) Analysis: - Identify additive or antagonistic effects on primary longevity pathways (e.g., mTOR, AMPK, Sirtuins, IGF-1).
- Flag “stack-on-stack” toxicity (e.g., multiple compounds affecting the same pathway or organ system).
-
Risk Stratification Philosophy:
- High Risk: Documented clinical contraindications, life-threatening potential (e.g., Serotonin Syndrome, QT prolongation, severe hepatotoxicity), or significant reduction in efficacy of critical meds.
- Medium Risk: Likely to require dose adjustment or biomarker monitoring (ALT/AST, Creatinine, HbA1c).
- Low Risk: Theoretical interactions based on in vitro data or animal models without established clinical significance in humans.
Output Format
Generate a prioritized Markdown table with the following columns: [Interaction Pair], [Risk Level], [Mechanism], [Potential Clinical Outcome], [Recommended Action/Investigation].
Follow the table with a “Knowledge Gaps” section identifying where human clinical data is missing for these specific combinations.
Style & Formatting
- Tone: “Tell it like it is.” Objective, clinical, and critical.
-
Format: Pure Markdown. No LaTeX. Do not use LaTeX or special characters that break simple text parsers.
• • Citations: Embed direct hyperlinked URLs (e.g., Smith et al., 2024) for all external data. Use nlm.nih.gov, doi.org, or nature.com as priority sources.
How to Use This Prompt Effectively
To ensure the analysis meets your standards for academic rigor, consider these three execution strategies:
1. Differentiate “In Vitro” vs. “In Vivo”
Many supplements (e.g., Curcumin, Quercetin) are potent inhibitors of enzymes in a petri dish but have poor bioavailability or different metabolites in vivo. If the AI flags a “High Risk” based on a test-tube study, you should challenge it to provide the Area Under the Curve (AUC) change reported in human trials.
2. Focus on “Narrow Therapeutic Index” (NTI)
If your stack includes medications where small dose changes lead to toxicity (e.g., Rapamycin/Sirolimus, Lithium, Warfarin, Digoxin, or Thyroid hormones), ensure the prompt specifically highlights **CYP3A4 and P-glycoprotein (P-gp)**competition, as these are the primary drivers of Sirolimus blood level fluctuations.
3. The “Longevity Pathway” Check
Since your interest is in longevity, an interaction isn’t just about safety—it’s about efficacy. For example:
- Antagonism: Taking a strong antioxidant alongside a “hormetic” stressor (like Zone 2 exercise or Metformin) might blunt the signaling response you are trying to elicit.
- Redundancy: Taking multiple mTOR inhibitors simultaneously may cross the threshold from “beneficial autophagy” into “immune suppression.”
Example Risk Table Output Structure
When you run the prompt, you should expect a result formatted like this:
| Interaction Pair | Risk Level | Mechanism | Potential Clinical Outcome | Recommended Action |
|---|---|---|---|---|
| Rapamycin + Grapefruit Juice | High | CYP3A4 Inhibition | 300-500% increase in Sirolimus AUC | Avoid co-administration; monitor trough levels. |
| Metformin + Bernerine | Medium | Additive AMPK activation / OCT1 competition | Risk of gastrointestinal distress or rare lactic acidosis | Monitor blood glucose; staggered dosing. |
| Glucosamine + Warfarin | Low | Potential INR elevation (mechanistically unclear) | Minor increase in bleeding risk | Check INR 72 hours after initiation. |